Background: This study uses the data collected from the "Partnership in Implementation Science for Geriatric Mental Health (PRISM)" project, a randomized trial designed to test implementation support strategies for the delivery of the Reducing Disability in Alzheimer's Disease (RDAD) program, an evidence-based multi-component exercise and behavioral/psychosocial intervention for older adults with dementia and their family caregivers in Thailand.
Method: A total of 353 dyads of persons with dementia (PwD) and behavioral and psychological symptoms of dementia (BPSD) and their family caregivers received a 12-week RDAD intervention and were assessed at baseline, and at 3- and 6-months post-treatment. Longitudinal analyses were conducted using paired-sample t-tests to estimate the changes in each of the outcomes by treatment groups.
Result: Paired t-tests showed that between baseline and 3 months, there were significant decreases in caregiver clinical outcomes, including caregiver burden (p = 0.047), depressive symptoms (p = 0.02), and BPSD-related caregiver distress (p < 0.001). Similarly, there were significant decreases between baseline and 3 months in PwD's mental health indicators, including BPSD symptoms (p < 0.001), BPSD severity (p < 0.002), and depression (p < 0.001). PwDs also showed a significant increase in physical function assessed by ADLs (p < 0.031) and cognitive function, as assessed by the Thai MMSE (TMSE) (p < 0.001), and these trends persisted between the 3- and 6-month follow-up assessments, with significant increases in ADLs (p < 0.001) and TMSE (p < 0.001). We also conducted heterogeneity regression analysis to assess whether the time changes might be determined by baseline characteristics (e.g., sex, age, subgroups) and found no significant influences of these factors on changes in outcomes over time.
Conclusion: The results suggest that the RDAD intervention significantly reduces caregivers' psychological burden, depressive symptoms, and BPSD-related distress and also improves the PwD's mental, physical, and cognitive function. These findings provide evidence that supports efforts to expand the reach of US-developed evidence-based non-pharmacological interventions to improve dementia care for community dwellers in resource-limited settings like Thailand.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.085980 | DOI Listing |
Alzheimers Dement
December 2024
Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, U.S.A., Philadelphia, PA, USA.
Background: The vicious cycle between depression and dementia increases the risk of Alzheimer's Disease (AD) pathogenesis and pathology. This study investigates therapeutic effectiveness versus side effects and the underlying mechanisms of intranasal dantrolene nanoparticles (IDNs) to treat depression behavior and memory loss in 5XFAD mice.
Method: 5XFAD and wild-type B6SJLF1/J mice were treated with IDNs (IDN, 5 mg/kg) in Ryanodex formulation for a duration of 12 weeks.
Background: In Alzheimer's Disease trials, the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) are commonly utilized as inclusionary criteria at screening. These measures, however, do not always reaffirm inclusionary status at baseline. Score changes between screening and baseline visits may imply potential score inflation at screening leading to inappropriate participant enrollment.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.
Background: In preparation for therapeutic trails involving patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), there is a need for valid, disease-specific caregiver-reported outcome (CRO) measures capable of tracking symptomatic burden in response to therapy over time. CROs are useful tools in clinical trials for individuals with AD, MCI, and dementia who are unable to self-report. In addition, CROs are accepted by the United States Food and Drug Administration to support regulatory claims.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Southern California, Los Angeles, CA, USA.
Background: Blood pressure (BP) management is an accessible therapeutic target for dementia prevention. BP variability (BPV) is a newer aspect of BP control recently associated with cognitive decline, dementia and Alzheimer's disease (AD), independent of traditionally targeted mean BP levels. Most of this work has relied on largely non-Hispanic White study samples in observational cohorts.
View Article and Find Full Text PDFIt is well recognised that Alzheimer's disease and related dementia disorders (ADRD) are associated with very high societal costs. The total global costs of dementia have been estimated to over 1.3 trillion US$ annually (Wimo, Seeher et al.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!